Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea

How to Cite:Kim H I, Kim I H, Jeon B J, Lee S, Kim S H, et al. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea.Hepat Mon.2012;12(7):430-436.https://doi.org/10.5812/hepatmon.6170.

Abstract

Background: The prevalence of hepatitis C virus (HCV) infections in elderly patients has been increasing in a number of countries. A few reports concerning pegylated interferon-α (PEG-IFN-α)-based combination treatment in elderly chronic hepatitis C (CHC) patients have been published, with slightly different treatment outcomes.
Objectives: We investigated the treatment response and safety of PEG-IFN-α plus ribavirin combination therapy in elderly patients with CHC.
Patients and Methods: Among a total of 181 treatment-naïve CHC patients (60 patients with genotype 1, 121 patients with genotype 2 or 3), 38 were aged ≥ 65 years (defined as the elderly group) and 143 were aged < 65 years (defined as the non-elderly group).
Results: The overall sustained virologic response (SVR) was lower in the elderly group than in the non-elderly group, but it was not significantly different (65.8 % vs. 76.2 %, P = 0.15). In a subgroup analysis, among patients with genotype 1, the elderly group had a significantly lower SVR rate than the non-elderly group (30.8 % vs. 66.0 %, P = 0.03). However, the SVR rate in patients with HCV genotype 2 or 3 was comparable between the two groups (84.0 % vs. 81.3 %, P = 0.85). HCV genotype was significantly associated with SVR in the elderly patients (genotype 1 vs. 2 or 3, odds ratio: 0.18, 95% confidence interval: 0.000-0.869, P = 0.03). The incidence of premature discontinuation of treatment (21.1 % vs. 9.1 %, P = 0.05) and dose modification (52.6 % vs. 31.5 %; P = 0.02) due mainly to adverse events or laboratory abnormalities, were higher in the elderly group than in the non-elderly group.
Conclusions: PEG-IFN-α plus ribavirin combination therapy might be considered for elderly CHC patients, especially for genotype 2 or 3, with vigilant monitoring of adverse events.

Implication for health policy/practice/research/medical education:
The care of older patients with chronic hepatitis C (CHC) is one of the most important issues confronted by physicians. The results of this study suggest that PEG-IFN-α plus ribavirin combination therapy might be considered for elderly chronic hepatitis C patients, especially for genotype 2 or 3, with vigilant monitoring of adverse events.
Please cite this paper as:
Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, et al. Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in Elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):430-6. DOI: 10.5812/hepatmon.6170

Keywords

Chronic Hepatitis C

Ribavirin

Korea

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 11
Last Update: 11 hours ago
Scopus by Title: 0
Last Update: 11 hours ago
Scopus by Title (Ref): 0
Last Update: 13 years ago
CrossRef: 11
Last Update: 3 days ago

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Hyeong Kim:[PubMed][Scholar]
In Kim:[PubMed][Scholar]
Byung Jeon:[PubMed][Scholar]
Seok Lee:[PubMed][Scholar]
Seong Kim:[PubMed][Scholar]
Sang Kim:[PubMed][Scholar]
Seung Lee:[PubMed][Scholar]
Soo Lee:[PubMed][Scholar]
Dae Kim:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea

Abstract

Full Text

Crossmark

Checking

Last Update: 11 hours ago

Last Update: 11 hours ago

Last Update: 13 years ago

Last Update: 3 days ago